Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 28 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetic, ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.

The CNPV has an expedited review process of 1 to 2 months. According to the FDA, the "cornerstone" of the process is a 1-day ...

The US president’s sudden policy reversal on weight-loss drugs like Ozempic and Wegovy could reshape the global market, from ...

Understand the challenges and solutions around pharmacy benefits as costs rise and new drugs enter the market.

Long before he found himself in the middle of a multibillion-dollar takeover battle for a coveted new weight-loss drug, Whit ...